Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics (Nasdaq: DSGN) will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Design Therapeutics (Nasdaq: DSGN) will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York.
A live webcast and 30-day archive will be available in the investors section of the company’s website.
Details
News Market Reaction – DSGN
On May 28, the day this news came out, DSGN closed 3.24% below the previous close.
Data tracked by StockTitan Argus for the May 28 session.
Key Figures
- Conference date
- June 4, 2026
- Jefferies Global Healthcare Conference fireside chat
- Presentation time
- 1:25 p.m. ET
- Scheduled start time of fireside chat
- Webcast archive period
- ≥30 days
- Duration webcast will remain available after presentation
Historical Context
-
Four-week RESTORE-FA DT-216P2 data showing clinical and biomarker improvements.
-
Announcement of investor webcast to review RESTORE-FA trial data.
-
Q1 2026 results with $222.8M cash and multiple clinical readouts expected.
-
FY 2025 results and progress across three GeneTAC clinical programs.
-
Participation in Oppenheimer and Leerink investor conferences with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
renee@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.